Regenxbio Revenue Per Share vs Total Revenue Analysis

RGNX Stock

USD 14.35 0.24 1.70%

Regenxbio financial indicator trend analysis is much more than just breaking down Regenxbio prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Regenxbio is a good investment. Please check the relationship between Regenxbio Revenue Per Share and its Total Revenue accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regenxbio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Regenxbio Stock please use our How to Invest in Regenxbio guide.

Revenue Per Share vs Total Revenue

Revenue Per Share vs Total Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Regenxbio Revenue Per Share account and Total Revenue. At this time, the significance of the direction appears to have totally related.

The correlation between Regenxbio's Revenue Per Share and Total Revenue is 0.99. Overlapping area represents the amount of variation of Revenue Per Share that can explain the historical movement of Total Revenue in the same time period over historical financial statements of Regenxbio, assuming nothing else is changed. The correlation between historical values of Regenxbio's Revenue Per Share and Total Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Revenue Per Share of Regenxbio are associated (or correlated) with its Total Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Revenue has no effect on the direction of Revenue Per Share i.e., Regenxbio's Revenue Per Share and Total Revenue go up and down completely randomly.

Correlation Coefficient

0.99

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Revenue Per Share

The amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding.

Total Revenue

Total revenue comprises all receipts Regenxbio generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Most indicators from Regenxbio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Regenxbio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regenxbio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Regenxbio Stock please use our How to Invest in Regenxbio guide.Sales General And Administrative To Revenue is likely to rise to 1.49 in 2024, whereas Selling General Administrative is likely to drop slightly above 47.8 M in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	418.5M	58.2M	35.7M	33.9M
Total Revenue	470.3M	112.7M	90.2M	111.6M

Gross Profit Total Revenue

Regenxbio fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Total Liab	Total Current Assets	Common Stock	Short Long Term Debt Total	Net Tangible Assets	Current Deferred Revenue	Non Currrent Assets Other	Other Assets	Short Term Investments	Other Current Assets	Other Stockholder Equity	Deferred Long Term Liab	Long Term Investments
Total Assets		0.84	0.83	0.96	-0.57	-0.54	0.71	0.79	0.95	0.96	0.84	-0.63	0.89	0.89	0.96	-0.63	0.85	0.95	0.67	0.67	0.61	0.68	0.44	0.93	0.69	0.83
Other Current Liab	0.84		1.0	0.72	-0.24	-0.81	0.9	0.57	0.83	0.76	0.73	-0.48	0.79	0.9	0.78	-0.48	0.96	0.8	0.37	0.38	0.49	0.57	0.77	0.86	0.54	0.56
Total Current Liabilities	0.83	1.0		0.71	-0.17	-0.85	0.94	0.51	0.82	0.76	0.73	-0.49	0.8	0.89	0.78	-0.49	0.96	0.8	0.36	0.39	0.42	0.63	0.8	0.87	0.56	0.53
Total Stockholder Equity	0.96	0.72	0.71		-0.55	-0.43	0.6	0.72	0.92	0.93	0.76	-0.67	0.86	0.73	0.93	-0.67	0.69	0.96	0.73	0.76	0.6	0.69	0.37	0.89	0.7	0.87
Net Debt	-0.57	-0.24	-0.17	-0.55		-0.2	0.08	-0.93	-0.48	-0.63	-0.53	0.28	-0.35	-0.51	-0.61	0.28	-0.31	-0.42	-0.48	-0.36	-0.62	0.03	0.29	-0.31	-0.29	-0.59
Retained Earnings	-0.54	-0.81	-0.85	-0.43	-0.2		-0.93	-0.14	-0.46	-0.54	-0.55	0.48	-0.68	-0.63	-0.56	0.48	-0.77	-0.6	-0.04	-0.24	0.04	-0.66	-0.92	-0.75	-0.56	-0.09
Accounts Payable	0.71	0.9	0.94	0.6	0.08	-0.93		0.28	0.67	0.66	0.64	-0.49	0.76	0.77	0.68	-0.49	0.88	0.7	0.24	0.36	0.12	0.74	0.81	0.84	0.56	0.34
Cash	0.79	0.57	0.51	0.72	-0.93	-0.14	0.28		0.7	0.81	0.73	-0.41	0.58	0.78	0.81	-0.41	0.62	0.64	0.52	0.44	0.67	0.2	0.03	0.58	0.44	0.68
Non Current Assets Total	0.95	0.83	0.82	0.92	-0.48	-0.46	0.67	0.7		0.83	0.7	-0.53	0.8	0.84	0.84	-0.53	0.82	0.91	0.68	0.57	0.73	0.57	0.43	0.86	0.57	0.92
Cash And Short Term Investments	0.96	0.76	0.76	0.93	-0.63	-0.54	0.66	0.81	0.83		0.88	-0.67	0.9	0.84	1.0	-0.67	0.78	0.92	0.59	0.72	0.45	0.71	0.39	0.91	0.74	0.69
Net Receivables	0.84	0.73	0.73	0.76	-0.53	-0.55	0.64	0.73	0.7	0.88		-0.5	0.8	0.83	0.9	-0.5	0.77	0.78	0.64	0.51	0.34	0.65	0.4	0.81	0.59	0.51
Common Stock Total Equity	-0.63	-0.48	-0.49	-0.67	0.28	0.48	-0.49	-0.41	-0.53	-0.67	-0.5		-0.66	-0.44	-0.67	1.0	-0.45	-0.69	-0.36	-0.46	-0.17	-0.54	-0.36	-0.69	-0.69	-0.45
Common Stock Shares Outstanding	0.89	0.79	0.8	0.86	-0.35	-0.68	0.76	0.58	0.8	0.9	0.8	-0.66		0.78	0.91	-0.66	0.78	0.91	0.58	0.67	0.37	0.83	0.55	0.95	0.9	0.6
Total Liab	0.89	0.9	0.89	0.73	-0.51	-0.63	0.77	0.78	0.84	0.84	0.83	-0.44	0.78		0.86	-0.44	0.97	0.77	0.43	0.39	0.5	0.53	0.48	0.84	0.55	0.61
Total Current Assets	0.96	0.78	0.78	0.93	-0.61	-0.56	0.68	0.81	0.84	1.0	0.9	-0.67	0.91	0.86		-0.67	0.8	0.92	0.6	0.71	0.45	0.72	0.42	0.92	0.74	0.69
Common Stock	-0.63	-0.48	-0.49	-0.67	0.28	0.48	-0.49	-0.41	-0.53	-0.67	-0.5	1.0	-0.66	-0.44	-0.67		-0.45	-0.69	-0.36	-0.46	-0.17	-0.54	-0.36	-0.69	-0.69	-0.45
Short Long Term Debt Total	0.85	0.96	0.96	0.69	-0.31	-0.77	0.88	0.62	0.82	0.78	0.77	-0.45	0.78	0.97	0.8	-0.45		0.78	0.36	0.34	0.43	0.58	0.64	0.87	0.55	0.55
Net Tangible Assets	0.95	0.8	0.8	0.96	-0.42	-0.6	0.7	0.64	0.91	0.92	0.78	-0.69	0.91	0.77	0.92	-0.69	0.78		0.63	0.71	0.54	0.76	0.56	0.96	0.74	0.78
Current Deferred Revenue	0.67	0.37	0.36	0.73	-0.48	-0.04	0.24	0.52	0.68	0.59	0.64	-0.36	0.58	0.43	0.6	-0.36	0.36	0.63		0.39	0.63	0.41	0.0	0.54	0.46	0.77
Non Currrent Assets Other	0.67	0.38	0.39	0.76	-0.36	-0.24	0.36	0.44	0.57	0.72	0.51	-0.46	0.67	0.39	0.71	-0.46	0.34	0.71	0.39		0.22	0.74	0.21	0.61	0.54	0.54
Other Assets	0.61	0.49	0.42	0.6	-0.62	0.04	0.12	0.67	0.73	0.45	0.34	-0.17	0.37	0.5	0.45	-0.17	0.43	0.54	0.63	0.22		-0.04	0.09	0.38	0.21	0.83
Short Term Investments	0.68	0.57	0.63	0.69	0.03	-0.66	0.74	0.2	0.57	0.71	0.65	-0.54	0.83	0.53	0.72	-0.54	0.58	0.76	0.41	0.74	-0.04		0.53	0.82	0.68	0.36
Other Current Assets	0.44	0.77	0.8	0.37	0.29	-0.92	0.81	0.03	0.43	0.39	0.4	-0.36	0.55	0.48	0.42	-0.36	0.64	0.56	0.0	0.21	0.09	0.53		0.63	0.39	0.11
Other Stockholder Equity	0.93	0.86	0.87	0.89	-0.31	-0.75	0.84	0.58	0.86	0.91	0.81	-0.69	0.95	0.84	0.92	-0.69	0.87	0.96	0.54	0.61	0.38	0.82	0.63		0.79	0.65
Deferred Long Term Liab	0.69	0.54	0.56	0.7	-0.29	-0.56	0.56	0.44	0.57	0.74	0.59	-0.69	0.9	0.55	0.74	-0.69	0.55	0.74	0.46	0.54	0.21	0.68	0.39	0.79		0.43
Long Term Investments	0.83	0.56	0.53	0.87	-0.59	-0.09	0.34	0.68	0.92	0.69	0.51	-0.45	0.6	0.61	0.69	-0.45	0.55	0.78	0.77	0.54	0.83	0.36	0.11	0.65	0.43

Click cells to compare fundamentals

Regenxbio Account Relationship Matchups

Regenxbio fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	497.9M	708.2M	1.1B	833.3M	574.0M	487.0M
Other Current Liab	21.5M	67.9M	114M	95.4M	100.3M	105.3M
Total Current Liabilities	33.7M	81.4M	130.5M	130.4M	130.3M	136.8M
Total Stockholder Equity	450.2M	377.8M	764.3M	516.2M	311.7M	348.3M
Net Debt	(58.2M)	(265.8M)	(258.5M)	(2.2M)	54.8M	57.5M
Retained Earnings	(177.8M)	(289.1M)	(161.2M)	(441.6M)	(705.0M)	(669.8M)
Accounts Payable	6.4M	10.6M	11.4M	27.2M	22.8M	23.9M
Cash	69.5M	338.4M	345.2M	97.0M	34.5M	32.8M
Non Current Assets Total	152.9M	177.0M	595.1M	417.3M	239.0M	200.1M
Cash And Short Term Investments	296.2M	475.7M	457.4M	364.6M	275.3M	255.6M
Net Receivables	38.1M	43.0M	32.4M	28.1M	26.3M	18.3M
Common Stock Shares Outstanding	36.7M	37.3M	43.9M	43.2M	43.7M	33.3M
Liabilities And Stockholders Equity	497.9M	708.2M	1.1B	833.3M	574.0M	487.0M
Total Liab	47.7M	330.4M	349.6M	317.1M	262.2M	138.7M
Total Current Assets	345.0M	531.2M	518.8M	416.0M	335.0M	286.9M
Short Long Term Debt Total	11.3M	72.7M	86.7M	94.8M	89.3M	57.0M
Net Tangible Assets	450.2M	377.8M	764.3M	516.2M	593.6M	386.3M
Non Currrent Assets Other	10.0M	9.9M	10.7M	9.9M	4.8M	8.1M
Other Assets	10.0M	8.8M	1.1B	9.9M	11.4M	10.8M
Short Term Investments	226.7M	137.3M	112.2M	267.7M	240.7M	168.1M
Other Current Assets	4.2M	2.0M	10.2M	9.4M	33.4M	35.0M
Other Stockholder Equity	627.8M	667.2M	928.1M	973.1M	1.0B	631.1M
Long Term Investments	103.8M	50.1M	394.2M	200.6M	38.9M	36.9M
Property Plant Equipment	39.1M	56.5M	192.5M	206.8M	237.8M	249.7M
Other Liab	5.2M	178.8M	134.2M	97.8M	112.5M	58.5M
Property Plant And Equipment Net	39.1M	120.3M	192.5M	206.8M	192.6M	98.2M
Retained Earnings Total Equity	(83.0M)	(177.8M)	(289.1M)	(161.2M)	(145.1M)	(152.4M)
Non Current Liabilities Total	14.0M	249.0M	219.1M	186.6M	132.0M	99.8M
Capital Surpluse	592.6M	627.8M	667.2M	928.1M	1.1B	586.6M
Inventory	6.5M	10.5M	18.8M	13.9M	16.0M	8.7M
Property Plant And Equipment Gross	39.1M	120.3M	192.5M	206.8M	249.8M	262.3M
Accumulated Other Comprehensive Income	205K	(360K)	(2.6M)	(15.4M)	(4.4M)	(4.2M)
Net Invested Capital	450.2M	377.8M	764.3M	516.2M	311.7M	489.0M
Net Working Capital	311.4M	449.8M	388.4M	285.5M	204.7M	331.4M
Capital Lease Obligations	11.3M	72.7M	86.7M	94.8M	89.3M	66.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
BAC	Bank of America
GM	General Motors

When determining whether Regenxbio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regenxbio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regenxbio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regenxbio Stock:

How To Invest In Regenxbio

Details

Is Regenxbio Stock a good investment?

Details

What is Regenxbio's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regenxbio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Regenxbio Stock please use our How to Invest in Regenxbio guide.

You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Complementary Tools for Regenxbio Stock analysis

When running Regenxbio's price analysis, check to measure Regenxbio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regenxbio is operating at the current time. Most of Regenxbio's value examination focuses on studying past and present price action to predict the probability of Regenxbio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regenxbio's price. Additionally, you may evaluate how the addition of Regenxbio to your portfolios can decrease your overall portfolio volatility.

	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Transaction History View history of all your transactions and understand their impact on performance
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	CEOs Directory Screen CEOs from public companies around the world

Is Regenxbio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regenxbio. If investors know Regenxbio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regenxbio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(5.87)

Revenue Per Share

1.957

Quarterly Revenue Growth

(0.18)

Return On Assets

(0.24)

Return On Equity

(0.61)

The market value of Regenxbio is measured differently than its book value, which is the value of Regenxbio that is recorded on the company's balance sheet. Investors also form their own opinion of Regenxbio's value that differs from its market value or its book value, called intrinsic value, which is Regenxbio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regenxbio's market value can be influenced by many factors that don't directly affect Regenxbio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Regenxbio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regenxbio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regenxbio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Regenxbio Revenue Per Share vs Total Revenue Analysis

Revenue Per Share vs Total Revenue

Revenue Per Share vs Total Revenue Correlation Analysis

Correlation Coefficient

Revenue Per Share

Total Revenue

Regenxbio fundamental ratios Correlations

Regenxbio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Regenxbio fundamental ratios Accounts

Also Currently Popular

Complementary Tools for Regenxbio Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Liabilities	+ 1.0	Other Current Liab
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 1.0	Common Stock Total Equity
Short Long Term Debt Total	+ 0.97	Total Liab
Total Stockholder Equity	+ 0.96	Total Assets
Cash And Short Term Investments	+ 0.96	Total Assets

Accounts Payable	- 0.93	Retained Earnings
Cash	- 0.93	Net Debt
Other Current Assets	- 0.92	Retained Earnings
Retained Earnings	- 0.85	Total Current Liabilities
Retained Earnings	- 0.81	Other Current Liab
Short Long Term Debt Total	- 0.77	Retained Earnings